José Ignacio De Granda-Orive

Dr. José Ignacio De Granda-Orive


Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 April 2022 in Archivos de Bronconeumología
Verified
Journal Article
Closed access
ECEusebi Chiner-Vives
Eusebi Chiner-Vives
RCRosa Cordovilla-Pérez
Rosa Cordovilla-Pérez
DRDavid de la Rosa-Carrillo
David de la Rosa-Carrillo
MGMarta García-Clemente
Marta García-Clemente
JIJosé Luis Izquierdo-Alonso
José Luis Izquierdo-Alonso
JGJosé Ignacio De Granda-Orive
José Ignacio De Granda-Orive

30 June 2013 in Revista española de Documentación Científica
Verified
Journal Article
Open access
PDF file
JGJosé Ignacio De Granda-Orive
José Ignacio De Granda-Orive
AAAdolfo Alonso-Arroyo
Adolfo Alonso-Arroyo
FGFrancisco Garcia-Rio
Francisco Garcia-Rio
SSSegismundo Solano-Reina
Segismundo Solano-Reina
CJCarlos Andrés Jiménez-Ruiz
Carlos Andrés Jiménez-Ruiz
RARafael Aleixandre-Benavent
Rafael Aleixandre-Benavent
El objetivo de este trabajo es comparar entre Web of Science (WoS) y Scopus los indicadores bibliométricos básicos del área de tabaquismo de autores españoles en el período 2000-2009. Métodos: La búsqueda se realizó en el SCI-Expanded y Scopus (“smok*” OR “tobac*”). Resultados: La media total anual del nº de documentos fue de 41 ± 12 para WoS vs 60 ± 16 en Scopus (p = 0,007). Aumento progresivo del índice de colaboración. La media anual del índice de colaboración fue de 9,41 ± 2,73 en WoS vs 7,12 ± 1,52 en Scopus (p = 0,029). Mayor número de citas con el paso del tiempo en ambas bases de datos pero son más recientes las citas en Scopus, el índice citas/artículo fue mayor en WoS (WoS 14,47 vs 11,50 Scopus). Conclusiones: Mayor número de revistas, trabajos, firmas y citas en Scopus comparado con WoS. El índice firmas/artículo e instituciones/artículo fue mayor en WoS. Incremento del índice de colaboración y mayor acúmulo de citas en los artículos más antiguos, pero más recientes en Scopus.

27 July 2023 in Archivos de Bronconeumología
Verified
Journal Article
Open access
CRCarlos Rábade-Castedo
Carlos Rábade-Castedo
JGJosé Ignacio De Granda-Orive
José Ignacio De Granda-Orive
JRJuan Antonio Riesco-Miranda
Juan Antonio Riesco-Miranda
EHEva De Higes-Martínez
Eva De Higes-Martínez
ÁRÁngela Ramos-Pinedo
Ángela Ramos-Pinedo
CJCarlos A. Jiménez-Ruiz
Carlos A. Jiménez-Ruiz
There are multiple systematic reviews and meta-analyses on the efficacy and safety of pharmacological treatments against nicotine dependence. However, there are few guidelines to answer frequent questions asked by a clinician treating a smoker. Therefore, the aim of this paper is to facilitate the treatment of tobacco addiction. 12 PICO questions are formulated from a GLOBAL PICO question: "Efficacy and safety of pharmacological treatment of tobacco dependence". A systematic review was carried out to answer each of the questions and recommendations were made. The GRADE (Grading of Recommendations, Assessment, Development and Evaluation) system was used to grade the certainty of the estimated effects and the strength of the recommendations. Varenicline, nicotine replacement therapy (NRT), bupropion and cytisine are more effective than placebo. Varenicline and combined nicotine therapy are superior to the other therapies. In smokers with high dependence, a combination of drugs is recommended, being more effective those associations containing varenicline. Other optimization strategies with lower efficacy consist of increasing the doses, the duration, or retreat with varenicline. In specific populations varenicline or NRT is recommended. In hospitalized, the treatment of choice is NRT. In pregnancy it is indicated to prioritize behavioral treatment. The financing of smoking cessation treatments increases the number of smokers who quit smoking. There is no scientific evidence of the efficacy of pharmacological treatment of smoking cessation in adolescents. The answers to the 12 questions allow us to extract recommendations and algorithms for the pharmacological treatment of tobacco dependence.

1 May 2009 in Gaceta Sanitaria
Verified
Journal Article
Open access
JGJosé Ignacio De Granda-Orive
José Ignacio De Granda-Orive
SVSantiago Villanueva-Serrano
Santiago Villanueva-Serrano
RARafael Aleixandre-Benavent
Rafael Aleixandre-Benavent
JVJuan Carlos Valderrama-Zurián
Juan Carlos Valderrama-Zurián
AAAdolfo Alonso-Arroyo
Adolfo Alonso-Arroyo
GAGregorio González Alcaide
Gregorio González Alcaide
The aim of this study was to analyze patterns of scientific collaboration and the visibility generated by coauthorship of articles on smoking among different countries on a world-wide basis through the Science Citation Index-Expanded (SCI-expanded) from 1999 to 2003. We selected articles on smoking resulting from collaboration among different countries in the SCI-Expanded (1999-2003). The underlying networks of collaboration among countries were analyzed by comparing production (number of articles published), visibility (number of citations received) and centrality (node degree, intermediation and proximity). A total of 3,484 articles were obtained, in which 5,008 institutions from 79 countries participated. The most productive country was the United Kingdom, with Germany and France in the second and third places. The United Kingdom also published the largest number of articles with inter-institutional collaboration (570 articles), with the USA and Germany in second and third places. The USA published the largest number of articles with international collaboration with the United Kingdom and France in the second and third places. All countries received a greater number of citations for articles resulting from international and inter-institutional collaboration than for those performed without collaboration. Networks of collaboration were completely connected through a single component and the annual increase in size of these inter-country networks was due to new countries joining the periphery of the network. We found a positive correlation between international and inter-institutional collaboration and the number of citations received by articles on smoking research. The number of citations per year remained constant throughout the 5-year study period.

30 June 2021 in Tobacco Prevention & Cessation
Verified
Journal Article
Open access
JGJosé Ignacio De Granda-Orive
José Ignacio De Granda-Orive
JPJosé F. Pascual-Lledó
José F. Pascual-Lledó
SASantos Asensio-Sánchez
Santos Asensio-Sánchez
SSSegismundo Solano-Reina
Segismundo Solano-Reina
MGMarcos García-Rueda
Marcos García-Rueda
CJCarlos A. Jiménez-Ruiz
Carlos A. Jiménez-Ruiz
Introduction: The aim of this study was to explore the utility of measuring motivation to quit smoking as a predictor of abstinence maintenance among smokers who wanted to quit and who were included in a multicenter study conducted in daily clinical practice. Methods: This observational,...

13 September 2022 in Open Respiratory Archives
Verified
Journal Article
Open access
JGJosé Ignacio De Granda-Orive
José Ignacio De Granda-Orive
CJCarlos A. Jiménez-Ruiz
Carlos A. Jiménez-Ruiz
IUInmaculada Gorordo Unzueta
Inmaculada Gorordo Unzueta
EHEva de Higes-Martínez
Eva de Higes-Martínez
ECEva Cabrera-César
Eva Cabrera-César
CRCarlos Rábade-Castedo
Carlos Rábade-Castedo
The health damage caused by passive smoking is well known in closed public spaces such as workplaces, inside homes and restaurants. However, at present, the number of smokers in open public spaces such as terraces has increased and consequently a loss of the quality of the air breathed, increasing the concentration of particles and other contaminating agents, affecting the health of workers and customers, of these spaces. Multiple studies show that high exposure to tobacco smoke in these environments augments the risk of developing cardiorespiratory diseases, especially in the vulnerable population, but also respiratory infections. Tobacco smoke can be an excellent vehicle for transmitting viral particles, favoring coronavirus disease 2019 (COVID-19).